Expanded Access To Pembrolizumab from Cost-Savings Generated by Biosimilar Filgrastim (BIOSIM-FIL) in The Prophylaxis of Chemotherapy-Induced (FEBRILE) Neutropenia (CIN/FN)- Simulation Study
Abstract
Authors
A McBride S Balu K Campbell M Bikkina K MacDonald I Abraham